{"nct_id":"NCT00050778","title":"A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis","status":"COMPLETED","status_verified_date":"2015-01","start_date":"2002-12","start_date_type":null,"primary_completion_date":"2007-09","primary_completion_date_type":"ACTUAL","completion_date":"2010-01","completion_date_type":"ACTUAL","phases":["PHASE2"],"tickers":["SNY"]}